Annuncio • Apr 09

Curanex Pharmaceuticals Inc Highlights Five Additional Patient Cases Supporting Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Curanex Pharmaceuticals Inc. highlighted five additional patient cases that management believes further support the potential of its lead candidate in cancer cachexia, advanced cancer supportive care and other serious disease settings characterized by profound physical decline, inflammation, metabolic dysfunction and loss of functional capacity. The five newly highlighted cases follow the Company's previously disclosed case involving a senior dosimetrist at a premier cancer hospital in the Northeast, whose personal experience management believes provided an initial clinically relevant signal supporting the Company's strategic interest in cancer cachexia and supportive oncology. Taken together, management believes the growing body of patient accounts may suggest broader potential relevance of the Company's lead candidate in helping patients maintain or recover appetite, strength, physical condition, mobility, and quality of life in the setting of serious disease. The newly highlighted cases include: Advanced Thymic Carcinoma — 52-Year-Old Male Patient. This 52-year-old male patient was receiving care at Memorial Sloan Kettering Cancer Center (MSKCC) for advanced thymic carcinoma with pulmonary embolism, pulmonary hemorrhage, and bilateral lung and pleural metastases. The pleural tumor measured 9.9 × 3.3 cm and was visibly vascularized. His wife recounted that doctors had told them the pain in his left abdomen was so severe it could cause him to faint at any moment — and that if it happened outside the home, he might not make it back. His estimated survival was approximately one month. According to the patient's account, after taking the Company's product for approximately 20 days, all pain disappeared, night sweats resolved, hemoptysis stopped, analgesic injections were no longer needed, and his appetite and sleep improved. Visible reduction of the pleural tumor was also reported. According to the patient's account, his projected survival extended from weeks to more than one year with meaningful improvement in quality of life. Advanced Small Cell Lung Cancer (SCLC) — 55-Year-Old Female Patient. This 55-year-old female patient was initially evaluated in Flushing, New York, and subsequently referred to Memorial Sloan Kettering Cancer Center (MSKCC) for treatment of metastatic small cell lung cancer. She had visible tumors in her neck, chest, and abdomen, with the largest neck tumor measuring approximately 1 × 1 cm. Her oncologist had told her family to prepare for her passing, saying she had only weeks to live. She had exhausted chemotherapy, radiotherapy, immunotherapy, and investigational therapies. Before taking the Company's product, she was profoundly cachectic, severely weak, and barely able to eat. According to the patient's account, within approximately one month, she gained about 17 pounds (~7.7 kg), her voice returned from weak to strong, and she resumed normal eating and physical activity. After approximately two months, she was walking briskly and jogging lightly, and the previously visible neck tumor was no longer detectable. According to the patient's account, her projected survival extended from weeks to more than three years. Pancreatic Cancer with Post-Surgical Multi-Organ Complications — 80-Year-Old Male Patient. This 80-year-old male patient developed multi-organ failure following pancreatic cancer resection and was hospitalized for an extended period at NewYork-Presbyterian Hospital in Lower Manhattan. The hospital had notified his family of his critical condition, with expected survival of only days or hours. He was unable to eat, had severe edema in his feet and legs, was severely hypotensive, bedridden, and required nasogastric tube feeding. According to the patient's account, the morning after taking the Company's product, he was able to eat small amounts that same evening; within a week, he could eat normally, and his blood pressure and liver and kidney function had returned to normal. Within two weeks, he had regained sufficient strength to be discharged home. After returning home, he went outside daily in a wheelchair for exercise and fresh air, and his mental state continued to improve. According to the patient's account, his projected survival extended from hours to more than one year with substantial improvement in condition and quality of life. End-Stage Liver Cirrhosis with Massive Ascites and Hepatorenal Syndrome — 82-Year-Old Male Patient, Chris. Chris, an 82-year-old male patient who had been under the long-term care of physicians at MSKCC, developed end-stage liver cirrhosis with massive ascites, causing his abdomen to swell to the size of a full-term pregnancy. He was extremely weak, unable to get out of bed independently, unable to walk, barely able to eat, and had been unable to urinate spontaneously for over a year, relying on daily drainage of ascitic fluid. After being told no further treatment options were available, he entered hospice care with an estimated life expectancy of one to two months. According to the patient's account, on the fourth day after taking the Company's product, he urinated in large quantities, and his appetite returned. By day eleven, the drainage tube had stopped producing fluid. After one month, he was using a walker and riding a stationary bicycle to exercise his legs, and was eating regularly. After two months, he was walking freely and cooking in the kitchen — and the abdomen had completely returned to normal. After three months, he had the energy to walk normally. According to the patient's account, he subsequently survived for more than one year with improved mobility and quality of life. End-Stage Renal Disease (ESRD) with Pleural Effusion, Hydronephrosis and Neuropathic Pain — 76-Year-Old Male Patient. This 76-year-old male patient with end-stage renal disease had been receiving thrice-weekly hemodialysis at North Flushing Dialysis Center. He was physically weak and could only walk slowly with a cane, suffering from severe bilateral leg pain, severe pleural effusion, hydronephrosis, and complete loss of spontaneous urination. According to the patient's account, spontaneous urination returned within approximately one week of taking the Company's product. Follow-up imaging subsequently confirmed complete resolution of both pleural effusion and hydronephrosis, bilateral leg pain fully resolved, and his physical strength recovered significantly. His mental state and overall condition continued to improve, and he was able to walk more than 10,000 steps per day independently, without any assistive device. Management noted that across these five cases, spanning very different disease backgrounds, a consistent set of themes emerged: severe weakness, loss of appetite, impaired mobility, profound physical deterioration, metabolic instability, and loss of independent function.

Percentuale dello stipendio del CEO	93.13%
Mandato del CEO	2.6yrs
Proprietà del CEO	22.6%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	1.6yrs

Data	Compenso totale	Stipendio	Utili della società
Jun 30 2026	n/a	n/a	-US$10m
Mar 31 2026	n/a	n/a	-US$7m
Dec 31 2025	US$233k	US$217k	-US$4m

Nome	Posizione	Mandato	Compensazione	Proprietà
Jun Liu	CEO, President & Chairman	2.6yrs	US$232.66k	22.56% $ 1.6m
Wanjun Zhang	Chief Financial Officer & Treasurer	less than a year	Nessun dato	Nessun dato
Liqin Xie	Chief Operating Officer	2.3yrs	Nessun dato	Nessun dato
Ning Zhang	Chief Technology Officer	2.3yrs	Nessun dato	Nessun dato
Huijuan Zhong	Chief Science Officer & Director	2.3yrs	Nessun dato	Nessun dato
Dian Jing	Secretary	8.3yrs	Nessun dato	38.72% $ 2.8m

Nome	Posizione	Mandato	Compensazione	Proprietà
Jun Liu	CEO, President & Chairman	2.3yrs	US$232.66k	22.56% $ 1.6m
Huijuan Zhong	Chief Science Officer & Director	1.6yrs	Nessun dato	Nessun dato
Daniel Pascheles	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Xiaohui Hao	Independent Director	2.3yrs	Nessun dato	Nessun dato
Yong Yan	Independent Director	2.3yrs	Nessun dato	Nessun dato
Nicholas Meanwell	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Helen Hsu	Independent Director	1.8yrs	Nessun dato	Nessun dato
Taku Kambayashi	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato
Selvakumar Subbian	Member of Scientific Advisory Board	less than a year	Nessun dato	Nessun dato

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/09/13 03:25
Prezzo dell'azione a fine giornata	2026/09/11 00:00
Utili	2026/06/30
Utili annuali	2025/12/31

Curanex Pharmaceuticals Gestione

Criteri Gestione verificati 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Curanex Pharmaceuticals Inc Announces Appointments to Scientific Advisory Board

Curanex Pharmaceuticals Inc Appoints Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell to Scientific Advisory Board

High number of new and inexperienced directors

Curanex Pharmaceuticals Inc Announces Executive Changes

High number of new and inexperienced directors

Recent updates

New minor risk - Share price stability

New major risk - Market cap size

Curanex Pharmaceuticals Inc Highlights Five Additional Patient Cases Supporting Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Curanex Pharmaceuticals Inc Expands Drug Development Pipeline to Include Cancer Cachexia

Curanex Pharmaceuticals Inc Achieves Key Preclinical Milestone with Favorable Toxicology Profile for Phyto-N Advancing Toward Ind Submission

Curanex Pharmaceuticals Inc Announces Appointments to Scientific Advisory Board

Curanex Pharmaceuticals Inc Appoints Dr. Daniel Pascheles and Dr. Nicholas A. Meanwell to Scientific Advisory Board

New major risk - Share price stability

Curanex Pharmaceuticals Inc. Provides Operational Update on Key Regulatory Milestones

High number of new and inexperienced directors

Curanex Pharmaceuticals Inc Announces Executive Changes

Curanex Pharmaceuticals Inc announced delayed 10-Q filing

Nasdaq Grants 180 Days Period to Curanex Pharmaceuticals to Regain Compliance

Curanex Pharmaceuticals Inc has completed an IPO in the amount of $15 million.

High number of new and inexperienced directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Gruppo dirigente

Membri del Consiglio di amministrazione

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC